Article
Dallas-Essilor Laboratories of America will add about $7 million in annual sales to its totals with the purchase of the assets of three laboratories in Phoenix, Tucson, and Denver.
NIH highlights 5 key elements of cortical visual impairment (CVI)
ROP: Treating and preventing blindness in preterm babies
Cerebral visual impairment is a growing concern in pediatric vision loss
Managing a changing landscape of IRD pediatric cases
FDA grants fast track status to FELIQS’ FLQ-101 for ROP
Cerebral visual impairment: A growing concern in pediatric vision loss